

558, 543

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau(43) International Publication Date
10 March 2005 (10.03.2005)

PCT

(10) International Publication Number
WO 2005/021709 A2(51) International Patent Classification⁷: C12N(21) International Application Number:
PCT/US2004/016969

(22) International Filing Date: 1 June 2004 (01.06.2004)

(25) Filing Language: English


(26) Publication Language: English

(30) Priority Data:
60/474,110 29 May 2003 (29.05.2003) US
60/556,239 25 March 2004 (25.03.2004) US(71) Applicant (for US only): **DIADEXUS, INC.** [US/US];
343 Oyster Point Boulevard, South San Francisco, CA
94080 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **DUAN, Xiaozhu**[US/US]; 208 Galway Bay, Alameda, CA 94502 (US).
KIM, Nam [CA/US]; 1187 Doyle Circle, Santa Clara,
CA 95054 (US). **WOLFERT, Robert, L.** [US/US]; 3582
Arbutus Avenue, Palo Alto, CA 94303 (US).(74) Agents: **LICATA, Jane, Massey et al.**; Licata & Tyrrell
P.C., 66 E. Main Street, Marlton, NJ 08053 (US).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,

[Continued on next page]

(54) Title: C1n101 ANTIBODY COMPOSITIONS AND METHODS OF USE ALONE AND IN COMBINATION WITH
PROSTATE SPECIFIC ANTIGEN AND OTHER CANCER MARKERS**Anti-C1n101 MAb Epitope Map**

(57) Abstract: This invention relates to a method for assessing risk of prostate and/or ovarian cancer. Specifically, in one embodiment it relates to utilizing both C1n101 and Prostate Specific Antigen (PSA) in combination to determine the risk of prostate cancer. In an alternative embodiment, the invention is relates to utilizing C1n101 alone or in combination with CA125 to determine the risk of ovarian cancer. The invention further provides isolated anti-prostate or ovarian cancer antigen (C1n101) antibodies that bind to C1n101 in vivo. The invention also encompasses compositions comprising an anti-C1n101 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-C1n101 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-C1n101 antibodies. The invention encompasses a method of producing the anti-C1n101 antibodies. Other aspects of the invention are a method of alleviating or

C1n101 -expressing cancer cell, comprising contacting the cancer cell with an anti-C1n101 antibody and a method of killing an
treating an C1n101 -expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-C1n101
antibody to the mammal.

WO 2005/021709 A2



ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

- *without international search report and to be republished upon receipt of that report*